The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

In a study published in the Lancet medical journal, Glaxo SmithKline’s AIDS drug Ziagen doubles the risk of heart attack.  In the wake of the published study, AIDS doctors are urging caution before abandoning the drug.  These antiretrovirals are wonderful and lifesaving, but they do have toxicity problems,” said Charlie Gilks, director of AIDS treatment and prevention at the World Health Organization. 

Not surprisingly, Glaxo’s spokesperson argued that internal company research does not support the Lancet findings. 

Comments are closed.

Of Interest